echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Axsome, a dual-mechanism drowsiness therapy, has been awarded over US$50 million to expand its neuroscience pipeline

    Axsome, a dual-mechanism drowsiness therapy, has been awarded over US$50 million to expand its neuroscience pipeline

    • Last Update: 2022-05-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 28, 2022, Axsome Therapeutics announced a definitive agreement with Jazz Pharmaceuticals to acquire Sunosi (solriamfetol)


    Narcolepsy is a disabling neurological disorder in which patients cannot properly regulate the cycle of sleep and wakefulness, resulting in symptoms of drowsiness


    Sunosi works through a dual mechanism to promote the patient's ability to stay awake


    References:

    [1] Jazz Pharmaceuticals Announces Agreement to Divest Sunosi® (solriamfetol) to Axsome Therapeutics.


    [2] Axsome Therapeutics to Acquire Sunosi® from Jazz Pharmaceuticals, Expanding Axsome's Leadership in Neuroscience.


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.